An administrative court run by the U.S. Patent and Trademark Office on Thursday rejected Moderna’s arguments to invalidate a U.S. patent owned by Arbutus, sparking worries over its efforts to develop next-generation vaccines, including a coronavirus vaccine. Moderna said the court’s ruling relates to actions it took in response to “longstanding aggressive posture” taken by Arbutus against developers of nucleic acid-based therapeutics and began well before the development of mRNA-1273, its COVID-19 vaccine candidate.
from Yahoo Finance https://ift.tt/2BsBG6E
Leave a Reply